美沙拉嗪联合布拉氏酵母菌散剂治疗溃疡性结肠炎患者的疗效评价

周长怀; 石光莲

doi:10.7619/jcmp.201921026

美沙拉嗪联合布拉氏酵母菌散剂治疗溃疡性结肠炎患者的疗效评价

Efficiency evaluation of mesalazine combined with saccharomyces boulardii powder in treatment of patients with ulcerative colitis

摘要

摘要:
目的探讨美沙拉嗪联合布拉氏酵母菌散剂治疗溃疡性结肠炎(UC)患者的疗效。
方法选取UC患者80例，随机分为2组各40例。对照组给予美沙拉嗪治疗，研究组给予美沙拉嗪联合布拉氏酵母菌散剂治疗。比较2组患者治疗效果、治疗前后炎症因子指标、肠黏膜病变程度以及复发率。
结果研究组总有效率97.50%, 显著高于对照组的77.50%(P < 0.05)。治疗后，研究组白细胞介素-17(IL-17)、IL-6水平均显著低于对照组(P < 0.05)。研究组治疗后的黏膜病变评分显著低于对照组(P < 0.05)。研究组复发率显著低于对照组(P < 0.05)。
结论美沙拉嗪联合布拉氏酵母菌散剂治疗UC安全、有效。

Abstract:
Objective To investigate the effect of mesalazine combined with saccharomyces boulardii powder in treatment of patients with ulcerative colitis (UC).
Methods Totally 80 UC patients were selected and randomly divided into two groups. The control group was treated with mesalazine, while the study group was treated with mesalazine combined with saccharomyces boulardii powder. The therapeutic effect, inflammatory factors before and after treatment, pathological changes of intestinal mucosa and recurrence rate were compared between the two groups.
Results The total effective rate of the study group was 97.50%, which was significantly higher than 77.50% of the control group (P < 0.05). After treatment, the levels of interleukin-17 (IL-17) and IL-6 in the studygroup were significantly lower than those in the control group (P < 0.05). The score of mucosal lesions in the study group was significantly lower than that in the control group (P < 0.05). The recurrence rate of the study group was significantly lower than that of the control group (P < 0.05).
Conclusion Mesalazine combined with saccharomyces boulardii powder is effective and safe in treatment of patients with UC.

HTML全文

参考文献(18)

施引文献

资源附件(0)